|1.||Sausville, Edward A: 4 articles (12/2006 - 12/2002)|
|2.||Narayanan, Ven L: 2 articles (03/2005 - 12/2003)|
|3.||Roy, Krishnendu K: 1 article (12/2006)|
|4.||Mukhopadhyay, Indranil: 1 article (12/2006)|
|5.||Doroshow, James H: 1 article (12/2006)|
|6.||Regev, Ronit: 1 article (07/2005)|
|7.||Yeheskely-Hayon, Daniella: 1 article (07/2005)|
|8.||Eytan, Gera D: 1 article (07/2005)|
|9.||Dann, Eldad J: 1 article (07/2005)|
|10.||Risbood, Prabhakar A: 1 article (03/2005)|
03/01/2005 - "Adaphostin (NSC 680410) has emerged as the improved compound with the maximum in vivo anti-leukemia hollow fiber activity, concordant with the original lead compound AG 957. "
12/08/2006 - "Adaphostin (NSC680410), a small molecule congener of tyrphostin AG957, has been demonstrated previously to have significant anti-proliferative effects in several leukemia models. "
02/15/2002 - "While AG957 has been purported to have specificity for the p210(bcr-abl) kinase, antiproliferative effects of AG957 in normal T-lymphocytes and bcr-abl negative leukemia cells suggest that other targets, such as c-CBL, may be substrates. "
12/01/2002 - "NSC 680410, the novel adamantyl ester of AG957, an inhibitor of the p210bcr/abl tyrosine kinase (CML, Ph(+)) and possibly other kinases, was tested for antitumor activity in ten human leukemia and human glioblastoma cell lines. "
|2.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/01/1996 - "AG957 is a tyrosine kinase antagonist which prior studies had shown inhibits p210bcr-abl tyrosine kinase activity and K562 chronic myelogenous leukemia cell growth. "
12/15/2003 - "Adaphostin (NSC 680410), an analog of the tyrphostin AG957, was previously shown to induce Bcr/abl down-regulation followed by loss of clonogenic survival in chronic myelogenous leukemia (CML) cell lines and clinical samples. "
01/01/2000 - "The tyrphostin AG957 (NSC 654705) inhibits p210bcr/abl, the transforming kinase responsible for most cases of chronic myelogenous leukemia (CML). "
07/01/2005 - "The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line."
02/15/2002 - "AG957 (NSC 654705) is a tyrphostin tyrosine kinase inhibitor that has been demonstrated previously to induce growth arrest in chronic myelogenous leukemia cells by inhibiting p210(bcr-abl) kinase activity and by stabilizing the association of p210(bcr-abl) kinase with its signaling adaptor molecules, Shc and Grb2. "
|3.||Acute Erythroblastic Leukemia (Erythroleukemia)
04/15/2003 - "The present study shows that ML formation occurs at two different stages of apoptosis induced in human erythroleukemia K562 cells by a brief (3 hr) exposure to paclitaxel (Taxol), an antitumour drug with a stabilising effect on microtubules, or to paclitaxel plus tyrphostin AG957, a selective inhibitor of the p210(BCR-ABL) tyrosine kinase activity. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Glioblastoma (Glioblastoma Multiforme)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|7.||Caspase 3 (Caspase-3)
|8.||Cytochromes c (Cytochrome c)
|9.||CD95 Antigens (fas Receptor)